Private Practices Would Bear 80% of the Nearly $1B Impact of CMS's Modifier 25 Proposal

Jiro Health estimates CMS's proposed 2027 Modifier 25 payment policy would reallocate $889.0 million annually in Medicare fee-for-service payments, with 81.5% ($724.4 million) of modeled reductions borne by private practices and solo physicians. Dermatology would absorb $395.4 million, or 44.5% of the total, while five additional specialties would account for roughly $336 million. More than 10,000 public comments referenced the proposal and about 85% explicitly opposed it; CMS is expected to finalize the 2027 Physician Fee Schedule this fall for implementation on January 1, 2027.

Analysis

The economically relevant effect is not the aggregate payment pool but the change in physician behavior: affected practices can preserve revenue by splitting evaluation and procedure encounters, raising patient friction, reducing same-day conversion, and increasing scheduling/staffing intensity. That creates a 6-18 month consolidation tailwind for scaled platforms with centralized billing, referral capture and capacity management, while independent specialty practices face lower owner compensation and reduced ability to invest in ancillaries. The likely first-order losers are private dermatology, ophthalmology, ENT, orthopedics and podiatry groups; the second-order risk is lower procedure throughput and consumable utilization rather than an immediate hit to drug manufacturers or device makers.

Public-market read-through is selective. Privia Health (PRVA) warrants monitoring because its network model depends on practice economics and physician retention, but its direct specialty mix and contractual exposure are not established; a directional short is premature. HCA Healthcare (HCA) and Tenet Healthcare (THC) could gain relative negotiating leverage if independent specialists seek hospital affiliation, yet any benefit is too dispersed to change near-term earnings. The cleaner near-term catalyst is the final fee schedule: a material revision, delay, or specialty carve-out would unwind concerns rapidly, especially given that the impact estimate originates from a vendor model rather than CMS's finalized scoring.

Consensus may overstate the revenue loss by assuming all affected encounters disappear economically. Many practices can reconfigure workflows, and a portion of the redistributed pool may return through annual conversion-factor mechanics; however, this mitigation is operationally harder for small offices and may still depress visit capacity. Over the next 1-3 months, watch final-rule language on modifier scope, the budget-neutrality conversion factor, and specialty-society litigation or legislative intervention. The thesis is falsified if CMS materially narrows eligible global procedures, exempts same-day medically necessary services, or delays implementation.

Key Decisions for Investors

• No immediate broad healthcare-services trade: the final-rule uncertainty and absence of disclosed issuer-level exposure make IHF/XLV positioning low signal-to-noise ahead of publication.
• Place PRVA on a negative catalyst watch through the final rule and next earnings call; only consider a 3-6 month short if management identifies meaningful dermatology/ophthalmology/orthopedic network exposure or guides to lower provider economics, retention, or care-margin contribution. Cover on a CMS carve-out or evidence that value-based contracts insulate affiliated practices.
• Monitor HCA and THC for incremental physician-practice acquisition commentary over the next 2-4 quarters; favor HCA over PRVA only if independent-specialist affiliation activity accelerates, as HCA has greater balance-sheet capacity and referral-capture infrastructure. This is a structural relative-value watch, not a pre-final-rule entry.
• For ophthalmology and dermatology procedure-device exposures such as BLCO and CUTR, treat any post-final-rule weakness as a volume-risk alert rather than a short: require evidence of reduced same-day procedure volumes in channel checks or quarterly utilization before acting. A workflow shift toward separate appointments could preserve, or even raise, procedure counts despite lower physician reimbursement.